AI-assisted, human-published
01/05/2024 /Funding Events
Vico Therapeutics Closes $60 Million Series B Funding for Neurological Disease Therapies
Vico Therapeutics secures $60 million financing led by Ackermans & van Haaren to drive the development of lead program VO659 for neurological diseases.
AI-assisted, human-published
Latest headlines
-
-
-
Stay connected!
If you have a serious, bonafide inquiry into the VentureCapital.com or PrivateEquity.com domain names, please contact us here
©2023 VentureCapital.com